In-Hospital Management Might Reduce Induction Deaths in Pediatric Patients With Acute Lymphoblastic Leukemia: Results From a Japanese Cohort

被引:4
|
作者
Nakagawa, Shunsuke [1 ]
Kato, Motohiro [2 ]
Imamura, Toshihiko [5 ]
Imai, Chihaya [6 ]
Koh, Katsuyoshi [7 ]
Kawano, Yoshifumi [1 ]
Shimomura, Yasuto [8 ]
Watanabe, Arata [10 ]
Kikuta, Atsushi [11 ]
Saito, Akiko [9 ]
Horibe, Keizo [9 ]
Manabe, Atsushi [3 ]
Ohara, Akira [4 ]
Okamoto, Yasuhiro [1 ]
机构
[1] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pediat, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan
[2] Natl Ctr Child Hlth & Dev, Childrens Canc Ctr, Tokyo, Japan
[3] St Lukes Int Hosp, Dept Pediat, Tokyo, Japan
[4] Toho Univ, Sch Med, Dept Pediat, Tokyo, Japan
[5] Kyoto Prefectural Univ Med, Dept Pediat, Kyoto, Japan
[6] Niigata Univ, Grad Sch Med & Dent Sci, Dept Pediat, Niigata, Japan
[7] Saitama Childrens Med Ctr, Dept Hematol Oncol, Saitama, Japan
[8] Aichi Med Univ, Sch Med, Dept Pediat, Nagakute, Aichi, Japan
[9] Nagoya Med Ctr, Natl Hosp Org, Clin Res Ctr, Nagoya, Aichi, Japan
[10] Nakadori Gen Hosp, Dept Pediat, Akita, Japan
[11] Fukushima Med Univ, Dept Pediat Oncol, Fukushima, Japan
关键词
chemotherapy; acute lymphoblastic leukemia; induction death; TREATMENT-RELATED MORTALITY; HIGH-DOSE METHOTREXATE; MAINTENANCE THERAPY; CHILDHOOD LEUKEMIA; INFECTIOUS DEATHS; RANDOMIZED-TRIAL; STANDARD-RISK; YOUNG-ADULTS; CHILDREN; CANCER;
D O I
10.1097/MPH.0000000000001926
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Induction deaths (ID) remain a critical issue in the treatment of pediatric patients with acute lymphoblastic leukemia (ALL). The reported rate of ID in this population is 1% or higher. We speculate that this proportion might be lower in Japan because of mandatory hospitalization during induction therapy to manage complications. We retrospectively analyzed the incidence of ID among children with ALL enrolled in 4 Japanese study groups between 1994 and 2013. Among 5620 children, 41 (0.73%) cases of ID were noted. The median age was 6.5 years; 24 children were female, and 7 had T-cell ALL. Infection was the most common cause of ID (n=22), but the incidence (0.39%) was lower than that reported in western countries. Mortality within 48 hours from the onset of infection was low, comprising 25% of infection-related deaths. The incidence of infections caused by Bacillus species was low. Only 1 patient died because of Aspergillus infection. Fatal infections mostly occurred during the third week of induction therapy. Our findings suggest that close monitoring, stringent infection control, and immediate administration of appropriate antibiotics through hospitalization might be important strategies in reducing the rate of infection-related ID in pediatric patients with ALL.
引用
收藏
页码:39 / 46
页数:8
相关论文
共 50 条
  • [31] Substitution with doxorubicin for daunorubicin during induction for high risk pediatric acute lymphoblastic leukemia results in increased toxicity
    Gardner, Rebecca A.
    Thomson, Blythe
    Hawkins, Douglas S.
    PEDIATRIC BLOOD & CANCER, 2013, 60 (02) : 338 - 339
  • [32] Epidemiological Characteristics and In-Hospital Management of Acute Coronary Syndrome Patients in Greece: Results from the TARGET Study
    Andrikpoulos, George
    Tzeis, Stylianos
    Mantas, Ioannis
    Olympios, Christoforos
    Kitsiou, Anastasia
    Kartalis, Athanasios
    Kranidis, Athanasios
    Tsaknakis, Themistoklis
    Richter, Dimitrios
    Pras, Athanasos
    Pipilis, Athanasios
    Lampropoulos, Stylianos
    Oikonomou, Kostas
    Gotsis, Alexandros
    Anastasiou-Nana, Maria
    Triposkiadis, Filippos
    Goudevenos, John
    Theodorakis, George
    Vardas, Panos
    HELLENIC JOURNAL OF CARDIOLOGY, 2012, 53 (01) : 33 - 40
  • [33] Bacterial heat shock protein genes during induction chemotherapy in pediatric patients with acute lymphoblastic leukemia
    Dunn, Katherine A.
    MacDonald, Emma
    MacDonald, Tamara
    Kulkarni, Ketan
    FUTURE ONCOLOGY, 2024, 20 (01) : 17 - 23
  • [34] EFFICACY AND FEASIBILITY OF FULL PEDIATRIC INDUCTION IN PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA ADULT PATIENTS
    Bisso, N.
    Guolo, F.
    Minetto, P.
    Clavio, M.
    Colombo, N.
    Kunkl, A.
    Ballerini, F.
    Guardo, D.
    Coviello, E.
    Gambella, M.
    Di Felice, N.
    Canale, F.
    Manconi, L.
    Todiere, A.
    Miglino, M.
    Lemoli, R. M.
    Gobbi, M.
    HAEMATOLOGICA, 2017, 102 : 80 - 80
  • [35] Immunoglobulin prophylaxis prevents hospital admissions for fever in pediatric acute lymphoblastic leukemia: results of a multicenter randomized trial
    Thus, Kirsten A.
    de Groot-Kruseman, Hester A.
    Winkler-Seinstra, Pauline
    Fiocco, Marta
    Segers, Heidi
    van den Bos, Cor
    van der Sluis, Inge M.
    Tissing, Wim J. E.
    Veening, Margreet A.
    Zwaan, Christian Michel
    van Tilburg, Cornelis M.
    Pieters, Rob
    Bierings, Marc
    HAEMATOLOGICA, 2025, 110 (01) : 47 - 54
  • [36] Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: Results from the NEUF study
    Locatelli, Franco
    Maschan, Alexey
    Boissel, Nicolas
    Strocchio, Luisa
    Alam, Naufil
    Pezzani, Isabella
    Brescianini, Alessandra
    Kreuzbauer, Georg
    Baruchel, Andre
    PEDIATRIC BLOOD & CANCER, 2022, 69 (04)
  • [37] Induction Mortality In Pediatric Acute Lymphoblastic Leukemia (ALL): a Retrospective Cohort Analysis From the Pediatric Health Systems Information (PHIS) Database, 1999-2009
    Seif, Alix E.
    Rheingold, Susan R.
    Fisher, Brian T.
    Huang, Yuan-Shung V.
    Li, Yimei
    Kersun, Leslie S.
    Bailey, L. Charles
    Reilly, Anne F.
    Aplenc, Richard
    BLOOD, 2010, 116 (21) : 1328 - 1329
  • [38] Dexrazoxane Use in Pediatric Patients With Acute Lymphoblastic or Myeloid Leukemia From 1999 and 2009: Analysis of a National Cohort of Patients in the Pediatric Health Information Systems Database
    Walker, Dana M.
    Fisher, Brian T.
    Seif, Alix E.
    Huang, Yuan-Shung V.
    Torp, Kari
    Li, Yimei
    Aplenc, Richard
    PEDIATRIC BLOOD & CANCER, 2013, 60 (04) : 616 - 620
  • [39] Mortality Among Pediatric Patients With Acute Lymphoblastic Leukemia in Sweden From 1988 to 2017
    Bjork-Eriksson, Thomas
    Bostrom, Martina
    Bryngelsson, Ing-Liss
    Lahteenmaki, Paivi M.
    Jarfelt, Marianne
    Kalm, Marie
    Olsson, Daniel S.
    JAMA NETWORK OPEN, 2022, 5 (11) : E2243857
  • [40] TPEN selectively eliminates lymphoblastic B cells from bone marrow pediatric acute lymphoblastic leukemia patients
    Mendivil-Perez, M.
    Velez-Pardo, C.
    Quiroz-Duque, L. M.
    Restrepo-Rincon, A.
    Valencia-Zuluaga, N. A.
    Jimenez-Del-Rio, Marlene
    BIOMETALS, 2022, 35 (04) : 741 - 758